Want to see HK:9939 full AI Analyst Report?
9939 Stock Chart & Stats
HK$1.69
-HK$0.05(-2.92%)
At close: 4:00 PM EDT
HK$1.69
-HK$0.05(-2.92%)
Day’s Range― - ―
52-Week RangeHK$1.60 - HK$4.70
Previous CloseN/A
Volume72.50K
Average Volume (3M)1.14M
Market Cap
HK$906.72M
Enterprise ValueHK$1.06K
Total Cash (Recent Filing)HK$31.79M
Total Debt (Recent Filing)HK$133.56M
Price to Earnings (P/E)―
Beta1.54
Next Earnings
Apr 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.41
Shares Outstanding498,660,100
10 Day Avg. Volume640,750
30 Day Avg. Volume1,139,483
Financial Highlights & Ratios
PEG Ratio-0.18
Price to Book (P/B)4.33
Price to Sales (P/S)24.23
P/FCF Ratio-4.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
2025 Revenue ReboundRevenue rebounded sharply in 2025, showing that the company can generate materially higher top-line activity after earlier weakness. If sustained, this provides a broader base for advancing its pipeline and could improve operating leverage as programs mature.
Proprietary Drug PipelineA proprietary small-molecule pipeline gives Kintor a defined asset base that can potentially create value through clinical progress, licensing, partnerships, or commercialization. This model offers multiple routes to future monetization if candidates achieve regulatory and market success.
Moderate LeverageModerate leverage limits the immediate burden of debt relative to many highly financed growth companies and preserves some balance-sheet flexibility. This can support continued research investment, although that benefit depends on controlling losses and cash consumption.
Bears Say
Persistently Negative ProfitabilityPersistently negative gross profit and continuing operating and net losses show that the business has not yet established sustainable economics. Even with losses narrowing from 2022–2023, deeply negative margins constrain internally funded development and keep the path to profitability uncertain.
Ongoing Cash BurnConsistently negative operating and free cash flow indicates that current activities consume rather than generate cash. Continued burn can require external funding before operations improve, increasing financing dependence and potentially limiting the company’s ability to advance several programs simultaneously.
Shrinking Equity BaseA materially shrinking asset and equity base signals that accumulated losses are eroding financial resources and shareholder capital. If this trajectory continues, the company may have less capacity to absorb setbacks, fund research internally, or maintain strategic flexibility without new capital.
Kintor Pharmaceutical Ltd News
9939 FAQ
What was Kintor Pharmaceutical Ltd’s price range in the past 12 months?
Kintor Pharmaceutical Ltd lowest stock price was HK$1.60 and its highest was HK$4.70 in the past 12 months.
What is Kintor Pharmaceutical Ltd’s market cap?
Kintor Pharmaceutical Ltd’s market cap is HK$906.72M.
When is Kintor Pharmaceutical Ltd’s upcoming earnings report date?
Kintor Pharmaceutical Ltd’s upcoming earnings report date is Apr 01, 2027 which is in 185 days.
How were Kintor Pharmaceutical Ltd’s earnings last quarter?
Kintor Pharmaceutical Ltd released its earnings results on Aug 19, 2026. The company reported -HK$0.175 earnings per share for the quarter.
Is Kintor Pharmaceutical Ltd overvalued?
According to Wall Street analysts Kintor Pharmaceutical Ltd’s price is currently Overvalued.
Does Kintor Pharmaceutical Ltd pay dividends?
Kintor Pharmaceutical Ltd does not currently pay dividends.
What is Kintor Pharmaceutical Ltd’s EPS estimate?
Kintor Pharmaceutical Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kintor Pharmaceutical Ltd have?
Kintor Pharmaceutical Ltd has 498,660,100 shares outstanding.
What happened to Kintor Pharmaceutical Ltd’s price movement after its last earnings report?
Kintor Pharmaceutical Ltd reported an EPS of -HK$0.175 in its last earnings report. Following the earnings report the stock price went up 2.941%.
Which hedge fund is a major shareholder of Kintor Pharmaceutical Ltd?
Currently, no hedge funds are holding shares in HK:9939
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kintor Pharmaceutical Ltd Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.60%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-14.14%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Kintor Pharmaceutical Ltd
Kintor Pharmaceutical Limited, a biotechnology firm in its clinical development phase, is dedicated to the discovery, advancement, and marketing of a diverse array of small molecule and biological therapies. The company primarily concentrates on androgen-receptor-related diseases that represent significant unmet medical needs, serving patients both in the People's Republic of China and globally. Its comprehensive pipeline of investigational products includes: Proxalutamide, a second-generation androgen receptor (AR) antagonist, being explored for the treatment of metastatic castration-resistant prostate cancer, AR-positive breast cancer, and COVID-19. Pyrilutamide, another AR antagonist, is under development for androgenetic alopecia (AGA) and acne vulgaris. An ALK-1 antibody targeting metastatic hepatocellular carcinoma (HCC) and various other solid tumors. GT20029, a topical AR-PROTAC compound, designed to address AGA and acne vulgaris. The dual-target antibody PD-L1/TGF-ß, intended for non-small cell lung cancer, biliary tract cancer, triple-negative breast cancer, and HPV-associated tumors. Detorsertib, which is being investigated for metastatic solid tumors such as breast cancer, prostate cancer, and HCC. A Hedgehog/SMO Inhibitor, an agent that blocks the hedgehog signal transduction pathway, aimed at treating blood cancer and basal-cell carcinoma. Founded in 2009, Kintor Pharmaceutical Limited is headquartered in Suzhou, People's Republic of China.
Technical Analysis
Alphamab Oncology
―
Jacobio Pharmaceuticals Group Co., Ltd.
―
3D Medicines, Inc.
―
CARsgen Therapeutics Holdings Ltd.
―
Ascentage Pharma Group International
―